Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

Tenofovir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 Randomized Trials

By Enthusiast Inc MDFebruary 27, 2015

Background: PEP is recommended after a potential exposure to HIV. In animal models, PEP has to be maintained 4 weeks to be effective. However, with the recommended regimens in humans,…

Tenofovir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 Randomized Trials

By Enthusiast Inc MDFebruary 27, 2015

Background: PEP is recommended after a potential exposure to HIV. In animal models, PEP has to be maintained 4 weeks to be effective. However, with the recommended regimens in humans,…

1125 – Tracking Equitable Rollout of Doxy-PEP and CAB-LA for STI & HIV Prevention in San Francisco Clinics

By Jimmy He PharmD, DScMarch 31, 2026

…The SF GTZ Consortium is monitoring rollout of doxy-PEP and CAB-LA prescribing in 3 large capacity SF clinics.  Methods Two sexual health clinics and one HIV clinic provided quarterly data…

DISTINCT CORD C-PEPTIDE, ADIPOKINE, AND LIPIDOMIC SIGNATURES BY IN UTERO HIV EXPOSURE

By Jimmy He PharmD, DScApril 27, 2020

Metabolic derangements early in life of HIV-exposed uninfected (HEU) infants have been reported. Pregnant HIV+ and HIV- women were enrolled with their infants in a US cohort from 2009-15. We measured insulin,…

IMPLEMENTATION OF A POST-EXPOSURE PROPHYLAXIS HOTLINE IN WASHINGTON, DC

By Jimmy He PharmD, DScApril 4, 2022

…nPEP telephone hotline paired with 5-7 day starter nPEP regimens through local contract pharmacies and follow up at a government run sexual health clinic. Callers who met nPEP CDC criteria,…

1278 – Acceptability of Doxycycline as Post-Exposure Prophylaxis in Southeastern Louisiana

By Jimmy He PharmD, DScMarch 20, 2025

…doxy PEP, and 67.6% (23/34) had prescribed it <5 times in the past 6 months. ID providers were more likely to have prescribed doxy PEP than other providers (41.2% vs…

1282 – The Actual Need for DoxyPEP Might Not Be as Large as Expected

By Jimmy He PharmD, DScMarch 20, 2025

…PrEP users assessing factors that describe individuals who might benefit most from doxyPEP. Methods Milano Checkpoint is a community-based, peer-led service that provides medical assistance to one of the largest…

1037 – DoxyPEP and Nongonococcal Urethritis in King County, WA: The Demise of Chlamydial NGU?

By Jimmy He PharmD, DScMarch 31, 2026

…to conduct clinic- and patient-level analyses, we evaluated trends in the etiology of NGU among both men who have sex with women (MSW) and men who have sex with men…

Doxy-PEP Effectiveness in Men Who Have Sex With Men (MSM) and Transgender Women (TGW) on HIV PrEP

By Jimmy He PharmD, DScMarch 6, 2024

Background: Doxycycline post-exposure prophylaxis (doxy-PEP) reduced the risk of chlamydia (CT), gonorrhea (GC) and early syphilis (ES) in MSM and TGW in randomized trials. Little is known about doxy-PEP effectiveness…

1282 – The Actual Need for DoxyPEP Might Not Be as Large as Expected

By Jimmy He PharmD, DScMarch 20, 2025

…users assessing factors that describe individuals who might benefit most from doxyPEP. Methods Milano Checkpoint is a community-based, peer-led service that provides medical assistance to one of the largest PrEP…

←1
234
…56789…
10111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top